# A Phase 2 Study of the Safety and Efficacy of Thymosin Beta 4 for Treating Corneal Wounds

> **NCT00598871** · PHASE2 · TERMINATED · sponsor: **ReGenTree, LLC** · enrollment: 12 (actual)

## Conditions studied

- Diabetes

## Interventions

- **DRUG:** Thymosin Beta 4 (Tβ4)
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00598871
- **Lead sponsor:** ReGenTree, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-12
- **Primary completion:** 2009-02
- **Final completion:** 2009-02
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** slow recruitment
- **Last updated:** 2015-07-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00598871

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00598871, "A Phase 2 Study of the Safety and Efficacy of Thymosin Beta 4 for Treating Corneal Wounds". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00598871. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*